Supplementary Materials and Methods

Preparation of DyLight755-trastuzumab conjugate
Anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab was mixed with DyLight755-NHS (Pierce, Rockford, IL) in bicarbonate buffer (pH = 9.0) at a 6:1 molar ratio of DyLight755-NHS:trastuzumab. After incubation at room temperature for 1 h, the DyLight755-trastuzumab conjugate, denoted as Dye755-anti-HER2, was purified using a PD-10 desalting column (GE Healthcare, Piscataway, NJ). The degree of labeling (dye:protein ratio) for Dye755-anti-HER2 was calculated to be 3.9 based on UV measurements of A 280 and A 755 .
In vivo simultaneous NIRF imaging of Dye-anti-CD206 and Dye755-anti-HER2
The A549 tumor-bearing nude mouse model was established by inoculating 5 × 10 6 tumor cells subcutaneously into the right front flanks of female BALB/c nude mice (4-5 weeks of age; Department of Laboratory Animal Science, Peking University). For the in vivo NIRF imaging study, three A549 tumor-bearing nude mice were intravenously injected with a mixture of 0. and Dye755-anti-HER2. The images indicated that HER2 (imaged by Dye755-anti-HER2; red) were nearly homogenously distributed within the tumor, whereas the tumor-infiltrating macrophages (imaged by Dye680-anti-CD206; green) were located mainly in the tumor center. (B) Immunofluorescence staining demonstrated that there was no overlay between HER2 (expressed on tumor cells) and CD206 (expressed on tumor-infiltrating macrophages) in A549 tumor tissue.
